153 related articles for article (PubMed ID: 26806023)
21. PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction.
Trendowski M
Pharmacol Res; 2015 Sep; 99():202-16. PubMed ID: 26117427
[TBL] [Abstract][Full Text] [Related]
22. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.
Cerchietti LC; Lopes EC; Yang SN; Hatzi K; Bunting KL; Tsikitas LA; Mallik A; Robles AI; Walling J; Varticovski L; Shaknovich R; Bhalla KN; Chiosis G; Melnick A
Nat Med; 2009 Dec; 15(12):1369-76. PubMed ID: 19966776
[TBL] [Abstract][Full Text] [Related]
23. Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects.
Chan CT; Paulmurugan R; Gheysens OS; Kim J; Chiosis G; Gambhir SS
Cancer Res; 2008 Jan; 68(1):216-26. PubMed ID: 18172314
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of purine-scaffold fluorescent probes for heat shock protein 90 with use in flow cytometry and fluorescence microscopy.
Taldone T; Gomes-DaGama EM; Zong H; Sen S; Alpaugh ML; Zatorska D; Alonso-Sabadell R; Guzman ML; Chiosis G
Bioorg Med Chem Lett; 2011 Sep; 21(18):5347-52. PubMed ID: 21802945
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic acidic nuclear phosphoproteins ANP32C/D are novel clients of heat shock protein 90.
Yuzefovych Y; Blasczyk R; Huyton T
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2338-48. PubMed ID: 26112988
[TBL] [Abstract][Full Text] [Related]
26. HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
Seipel K; Kohler S; Bacher U; Pabst T
Curr Issues Mol Biol; 2023 Aug; 45(9):7011-7026. PubMed ID: 37754227
[TBL] [Abstract][Full Text] [Related]
27. A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy.
Bryant KG; Chae YC; Martinez RL; Gordon JC; Elokely KM; Kossenkov AV; Grant S; Childers WE; Abou-Gharbia M; Altieri DC
Oncotarget; 2017 Dec; 8(68):112184-112198. PubMed ID: 29348817
[TBL] [Abstract][Full Text] [Related]
28. A purine analog synergizes with chloroquine (CQ) by targeting Plasmodium falciparum Hsp90 (PfHsp90).
Shahinas D; Folefoc A; Taldone T; Chiosis G; Crandall I; Pillai DR
PLoS One; 2013; 8(9):e75446. PubMed ID: 24098696
[TBL] [Abstract][Full Text] [Related]
29. Measuring Tumor Epichaperome Expression Using [
Jhaveri KL; Dos Anjos CH; Taldone T; Wang R; Comen E; Fornier M; Bromberg JF; Ma W; Patil S; Rodina A; Pillarsetty N; Duggan S; Khoshi S; Kadija N; Chiosis G; Dunphy MP; Modi S
JCO Precis Oncol; 2020; 4():. PubMed ID: 33283132
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
[TBL] [Abstract][Full Text] [Related]
31. PU-H71 effectively induces degradation of IκB kinase β in the presence of TNF-α.
Qu Z; Wang S; Teng R; Yi X
Mol Cell Biochem; 2014 Jan; 386(1-2):135-42. PubMed ID: 24114662
[TBL] [Abstract][Full Text] [Related]
32. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.
Guo A; Lu P; Lee J; Zhen C; Chiosis G; Wang YL
Oncogene; 2017 Jun; 36(24):3441-3449. PubMed ID: 28114285
[TBL] [Abstract][Full Text] [Related]
33. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
[TBL] [Abstract][Full Text] [Related]
34. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.
Moulick K; Ahn JH; Zong H; Rodina A; Cerchietti L; Gomes DaGama EM; Caldas-Lopes E; Beebe K; Perna F; Hatzi K; Vu LP; Zhao X; Zatorska D; Taldone T; Smith-Jones P; Alpaugh M; Gross SS; Pillarsetty N; Ku T; Lewis JS; Larson SM; Levine R; Erdjument-Bromage H; Guzman ML; Nimer SD; Melnick A; Neckers L; Chiosis G
Nat Chem Biol; 2011 Sep; 7(11):818-26. PubMed ID: 21946277
[TBL] [Abstract][Full Text] [Related]
35. Radiosynthesis, biological evaluation and preliminary microPET study of
Kang J; Young Lee J; Taş İ; More KN; Kim H; Park JH; Chang DJ
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3658-3664. PubMed ID: 30528977
[TBL] [Abstract][Full Text] [Related]
36. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.
He H; Zatorska D; Kim J; Aguirre J; Llauger L; She Y; Wu N; Immormino RM; Gewirth DT; Chiosis G
J Med Chem; 2006 Jan; 49(1):381-90. PubMed ID: 16392823
[TBL] [Abstract][Full Text] [Related]
37. Heat shock protein 90α inhibitor, PU-H71 in combination with DHEA promoting apoptosis in triple-negative breast cancer cell line MDA-MB-231.
Soudan H; Saeed H; Eldemellawy M; Shalaby M; Hassan M; Elkewedi M; El-Nikhely N
Acta Biochim Pol; 2020 Dec; 67(4):561-570. PubMed ID: 33319549
[TBL] [Abstract][Full Text] [Related]
38. Hsp90 inhibition aggravates adriamycin-induced podocyte injury through intrinsic apoptosis pathway.
Dong J; Jiang Z; Ma G
Exp Cell Res; 2020 May; 390(2):111928. PubMed ID: 32156599
[TBL] [Abstract][Full Text] [Related]
39. Improved synthesis of no-carrier-added p-[124I]iodo-L-phenylalanine and p-[131I]iodo-L-phenylalanine for nuclear medicine applications in malignant gliomas.
Israel I; Brandau W; Farmakis G; Samnick S
Appl Radiat Isot; 2008 Apr; 66(4):513-22. PubMed ID: 18024046
[TBL] [Abstract][Full Text] [Related]
40. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma.
Breinig M; Caldas-Lopes E; Goeppert B; Malz M; Rieker R; Bergmann F; Schirmacher P; Mayer M; Chiosis G; Kern MA
Hepatology; 2009 Jul; 50(1):102-12. PubMed ID: 19441108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
